Two pharmaceutical companies that have waited patiently to complete their $3.4 billion deal may proceed under strict conditions, though one Commissioner has questioned the ultimate effectiveness of the consent order....
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: